Celgene Raises the Bar in Immuno-Oncology with US$1 B Bet on JunoTherapeutics
By Heather Cartwright & Rohit Khera
Pharma Deals Review: Vol 2015 Issue 7 (Table of Contents)
Published: 16 Jul-2015
DOI: 10.3833/pdr.v2015.i7.2112 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In return for a staggering US$1 B upfront in cash and equity, Celgene has gained rights to access Juno Therapeutics’ pipeline of chimeric antigen receptor technology (CAR-T) and T-cell receptor (TCR) programmes over a 10-year period as it strives to become a leading player in immuno-oncology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS